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ABSTRACT
Introduction: To prove the feasibility and safety
of a conversion to once-daily injected GLP1 ago-
nist (lixisenatide) and long-acting basal insulin
analogue (glargine) in patients with T2DM and
poorly controlled glycemia previously treated
with multiple injections of premixed insulins
(iPremix) in an outpatient setting.
Methods: Nine patients with T2DM currently
receiving iPremix formulations and poor gly-
cemic control were switched to once-daily
injected lixisenatide (Lixi) and basal insulin
analogue glargine (iGlar) for a 12-week period.
Efficacy was defined as A1c reduction of at least
0.4% and weight loss of 0.5 kg or higher.
Results: Five of nine patients achieved A1c
reductions of 0.4% (4 mmol/mol) or higher and
six of nine patients a weight loss of 0.5 kg or
higher. A mean A1C reduction of 0.5% ± 0.5%
(6 mmol/mol) and mean weight loss of
-1.4 ± 3.6 kg were observed in all patients. Total
daily insulin dose after 12 weeks declined from
56 ± 26 IU with iPremix formulations to
47 ± 17 IU in patients taking combined iGlar and
Lixi. Corrections with fast acting insulin gluli-
sine (iGlu) were necessary in two patients on a
regular basis and in four patients on an irregular
basis (2.3 IU mean total daily dose). Two patients
did not need additional iGlu. Postprandial glu-
cose profiles were lower in the combined group
compared with iPremix throughout the day,
which resolved in the afternoon. No metabolic
derangements occurred. Mild hypoglycemia and
gastrointestinal symptoms were the most often
reported adverse events affecting three patients.
Conclusion: The conversion to once-daily
injected GLP1 agonist Lixi and basal iGlar could
safely be performed in an outpatient setting and
was associated with better postprandial gly-
cemic control throughout the day, except din-
ner, compared to iPremix.
Clinical Trial Registration: EU clinical trials
register EudraCT number 2013-005334-37 and
ClinicalTrials.gov NCT02168491.
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The prevalence of type 2 diabetes mellitus
(T2DM) is increasing worldwide with a dou-
bling of numbers expected within the next
three decades [1]. To overcome progressive
decline of insulin secretion over the years of
disease progression a subsequent dependency
on subcutaneous insulin administration fol-
lows oral glucose-lowering medication [2].
Obviously flexible, intensified insulin therapy
regimens would be the best option for these
patients to cover postprandial insulin need.
However, clinical inertia among physicians,
patient difficulties to manage T2DM with
complex therapeutic schemes, and/or lack of
patient adherence and health disparities might
hamper optimal glucose management [3]. In
Austria and several other countries around the
world premixed insulin (iPremix) regimens are
used routinely for treatment of those patients
in need of a simplified approach beyond basal
insulin, as the efficacy is widely proven, fewer
injections are necessary, and beneficial post-
prandial glucose levels compared with basal
insulin treatment are reported [2, 4]. However,
a well-known higher risk of hypoglycemia
exists [2, 4].
Recently new coformulations with combi-
nations of GLP1 receptor agonists (GLP1-RA)
and long-acting insulin analogues were laun-
ched and shown to be effective and safe in
treatment of T2DM [5–10]. However, it is
unknown if patients with T2DM previously
treated with iPremix with poorly controlled
glycemia are able to be treated effectively by a
new combined coformulation administered
once daily, potentially facilitating insulin
injection and possibly increasing adherence.
We hypothesized that a switch from iPremix
to a combination therapy of GLP1-RA lixisen-
atide (Lixi; Lyxumia, Sanofi, Paris, France) and
basal insulin glargine (iGlar; Lantus, Sanofi,
Paris, France) in patients with T2DM is practi-
cable in an outpatient setting. The aim of this
study was to prove the principle of feasibility,
effectiveness, and safety of once-daily injected
GLP1-RA lixisenatide (Lixi) and basal insulin
glargine (iGlar) combined in patients with
T2DM and poor glycemic control previously
treated with at least twice-daily iPremix.
METHODS
This study is an exploratory proof of principle,
monocentric, non-randomized clinical obser-
vation study including 11 patients with poorly
controlled T2DM with iPremix. Patients with
T2DM were recruited from the diabetes outpa-
tient ward of the Department of Endocrinology
and Metabolism at the Medical University of
Vienna/General Hospital Vienna, Austria. Glu-
cose metabolism was observed before treatment
start and compared with profiles after combined
treatment. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human experimen-
tation (institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
Main inclusion criteria included type 2 dia-
betes, age greater than 18 years and less than
75 years, A1c 7% to 11% (53–97 mmol/mol),
and written informed consent. Exclusion crite-
ria included women of reproductive age, loss of
hypoglycemia sensibility, oral glucose-lowering
medication except metformin, chronic liver or
kidney disease, dyslipidemia, history of pan-
creatitis or pancreatic tumors, and history of
psychiatric disease or autoimmune disease.
Recruitment started in December 2014 and las-
ted till July 2015.
After screening, patients were treated with
iPremix for another week. In this period home
glucose self-monitoring with at least seven daily
measurements was performed (fasting, before
main courses, 2 h after meals, before sleeping).
After 1 week, iPremix was changed to iGlar with
a dose reduction to 60% of the last total daily
iPremix dose. At the same time Lixi was started
with a dose of 10 lg/day with subsequent
up-titration to 20 lg/day after 2 weeks, if well
tolerated. iGlar dose was regularly up-titrated at
every study visit according to glucose profiles.
Total treatment duration was 12 weeks. To pre-
vent hyperglycemic events patients were
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trained to inject fast-acting insulin glulisine
(iGlu, Apidra, Sanofi, Paris, France) if glucose
levels exceed 200 mg/dl. Training was individ-
ualized and correction rates were adapted to
patients’ needs as follows: 200–250 mg/dl,
2 units; 250–300 mg/dl, 4 units; and greater
than 300 mg/dl, 6–8 units of fast-acting insulin
were injected by the patient. If glucose levels
exceed 400 mg/dl or glucose levels constantly
exceed 300 mg/dl, patients were instructed to
contact the study site immediately for further
instruction or hospitalization if necessary. At
every visit urinary testing for ketone bodies was
performed. To ensure safety in the first week
after switching from iPremix to combined Lixi
and iGlar, regular visits or telephone calls were
performed.
At screening, medical history and current
medication were obtained by questioning or
from medical records. The patient was exam-
ined by a trained physician to rule out any
condition excluding the patient from the trial.
Vital signs and a 12-lead ECG were performed.
Last menstruation time was asked in women to
examine reproductive function. Blood samples
were analyzed in our ISO9001 certified central
laboratory. All methods including reference
parameters are available from www.kimcl.at.
The use of glucometers was retrained for home
blood glucose self-monitoring, as well as main-
tenance of glucose profiles with several distinct
measure points.
Descriptive data analysis was performed for
all parameters. Continuous variables were
summarized by mean ± SD as well as median
and 25th and 75th percentiles and categorical
variables by counts and percentages. Clinical
efficacy was defined as A1c reduction of at least
0.4% (4 mmol/mol) and weight loss of at least
0.5 kg. Continuous variables were analyzed
using Wilcoxon signed-rank test. Given the
small sample size a non-parametric test was
used for paired samples. Areas under the curves
were calculated using trapezoidal rule.
Statistical analysis was performed using
SPSS 24.0 (SPSS Inc, Chicago, IL, USA) and
GraphPad Prism 5 (GraphPad Software Inc, La
Jolla, CA, USA). A two-sided p value less than
0.05 was considered statistically significant.
RESULTS
In total 11 patients with T2DM were screened,
two of whom discontinued immediately after
screening because of time limitations; thus nine
patients were switched to combined Lixi and
iGlar treatment of which two were female
(Table 1). Another patient finished prematurely
because of skepticism against new treatment
procedures, although an obvious amelioration
of glycemic control with A1c reduction from
10.7% (93 mmol/mol) to 9.6% (81 mmol/mol)
and no side effects were reported.
Twelve weeks combined Lixi and iGlar
treatment was associated with a reduction in
A1c of at least 0.4% (min. -0.4, max.-1.4%;
4 mmol/mol, min. -4, max. -15 mmol/mol) in
5 of 9 (56%) patients. In these responders a
mean reduction of A1C of 0.9 ± 0.4%
(10 ± 4 mmol/mol) was seen, whereas 3 of 9
(33%) non-responders had a reduction of only
0.1% and one patient had a 0.1% A1C increase
(1 mmol/mol both). A significant total A1c
reduction of 0.5 ± 0.5% (6 ± 6 mmol/mol) was
seen in all patients [Z = -2.44, 95% CI 0.1,
1.0% (1, 10 mmol/mol); p\0.02]. Only 1 of 9
(11%) patients achieved A1c less than 7.0%
(53 mmol/mol). A clear tendency of better
postprandial glycemic control was visible after
12 weeks of treatment with combined Lixi and
iGlar compared to iPremix (Fig. 1). This effect
was especially pronounced during the day and
was suspended in the evening. However, AUCs
were not significantly different (AUC iPremix
mean ± Std 2927.3 ± 772.9 mg/dl 9 min, med-
ian 3155.0 mg/dl 9 min, 25–75th percentile
2257.8–3469.3 mg/dl 9 min; AUC Lixi ? iGlar
2697 ± 807.6, 2781.0, 2207.0–3082.2 mg/
dl 9 min; Z = -1.36 p = 0.17).
In 6 of 9 (67%) participants a weight loss of
at least 0.5 kg (min. -0.6 kg, max. -7.8 kg) was
observed, two patients gained weight (2.8 and
4.1 kg), and one patient had no weight change
at all. In responders a mean weight loss of
-3.2 ± 2.5 kg and in all patients mean weight
loss of -1.4 ± 3.6 kg were observed (Z = -0.98,
95% CI -1.4, 4.1; p = 0.33).
Combined Lixi and iGlar was associated with
lower total daily insulin doses (47 ± 17 IU) after
Diabetes Ther
12 weeks treatment compared to iPremix alone
(56 ± 26 IU) at baseline, which was not signifi-
cantly different (Z = -1.72, 95% CI -2, 20;
p = 0.09).
As per study protocol and as a safety measure
we decided to reduce the basal insulin dose to
60% of the previously used iPremix. Especially
at the beginning nearly all patients had to cor-
rect with fast-acting insulin. After 12 weeks of
combined treatment additional iGlu corrections
were necessary on a regular (n = 2) or irregular
daily basis (n = 4). Two patients had no addi-
tional iGlu need (Table 2). Total daily insulin
doses of iPremix, iGlar, and iGlu per patient at
baseline and after 12 weeks of combined treat-
ment are shown in Table 2. In total a mean daily
iGlu dose of 2.3 IU was administered, and 92
self blood glucose measurements of 404 mea-
surements were above 200 mg/dl (22.8%)
compared to 141 elevated values of 305 mea-
surements at baseline (46.3%). The initial insu-
lin reduction was too high and we constantly
up-titrated iGlar doses to achieve accept-
able fasting glucose levels (Fig. 1), which was
unsuccessful.
During the 12 weeks one serious adverse
event in one female patient who underwent an
Table 1 Baseline characteristics of study participants with T2DM
N Mean Std Median 25th–75th percentile
Age (years) 9 65.0 6.1 66.0 60.5–70.5
Height (cm) 9 171.0 5.6 174.0 164.5–175.0
Weight (kg) 9 94.9 10.4 97.9 88.1–101.5
BMI (kg/m2) 9 31.0 3.4 32.0 28.8–33.1
BP sys (mmHg) 9 149 21 149 138–166
BP dia (mmHg) 9 79 11 78 72–85
HbA1c (%) 9 9.1 1.1 9.0 8.7–9.9
HbA1c (mmol/mol) 9 76 12 75 72–85
Heart rate (bpm) 9 84 7 86 81–89
Waist (cm) 9 112.0 5.7 112.0 107.5–117.5
Total daily insulin dose (U) 9 56.2 26.0 52.0 35.0–77.0
Diabetes duration (years) 9 12.1 5.2 10.0 9.0–16.0
Counts %
Caucasian ethnicity 9/9 100
Male sex 7/9 78
Postmenopausal femalea 2/2 100%
T2DM type 2 diabetes mellitus, N number, Std standard deviation, BMI body mass index, BP sys systolic blood pressure, BP
dia diastolic blood pressure
a Age of women in postmenopause (minimum–maximum), 57–70 years
Fig. 1 aMeans and standard deviations at each time point
of daily home blood glucose self-monitoring at baseline
(= iPremix, black) and after 12 weeks of combined
treatment (= iGlarLix, gray) with combined lixisenatide
and insulin glargine (no signiﬁcant difference for AUC or
fasting/postprandial glucose levels). b Insulin doses
throughout the study. c Pre and post graphs showing
changes of HbA1c. d Pre and post graphs showing changes





elective ENT surgery with no postsurgical com-
plications was reported. Several adverse events
have been reported, of which four were con-
sidered moderate and 18 of mild appearance.
Most often (n = 8) mild asymptomatic hypo-
glycemia was reported and one symptomatic
hypoglycemia was reported by three patients
(33%). Gastrointestinal complications were
reported in two patients (22%). Urinary tract
infections occurred in two patients (22%).
DISCUSSION
In this exploratory study we demonstrated that
poorly controlled patients with long-standing
T2DM and at least twice-daily iPremix can be
safely and effectively treated with once-daily
Lixi and iGlar. A majority of patients achieved
clinically significant A1c level and weight
reductions. A tendency towards an amelioration
of postprandial glucose profiles during the day,
except dinner, was seen using comparable
insulin doses. Adverse events reported in a few
patients were mostly mild hypoglycemia and
mild gastrointestinal complaints.
Latest guidelines from the American Dia-
betes Association recommend to consider a
combination of injectable therapies in patients
insufficiently treated with combined oral drugs
and basal insulin [11]. In these subjects one
option is to start with a combination of
GLP1-RA and basal insulin; other options
include adding fast-acting insulin before the
largest meal or changing to twice-daily pre-
mixed insulin injections. Further therapeutical
escalation is needed in those patients not
reaching A1c target goals or patients intolerant
to this combination. However, so far there are
no recommendations regarding patients not
achieving treatment goals and/or suffering from
hypoglycemia during treatment with multiple
daily injections of premixed insulin. This
highlights the clinical need for approaches that
allow changing the therapeutic strategy in sub-
jects with usually long-standing diabetes treated
with high insulin doses. With our proof of
principle study we could demonstrate that
patients with established premixed insulin
therapy injected at least twice daily can be
safely switched to a combination therapy of
GLP1-RA lixisenatide and basal insulin glargine
administered once daily.
This small study corroborates recent findings
of randomized controlled trials (RCTs) investi-
gating the effects and safety of various combi-
nations of once-daily Lixi with either iGlar
compared to iGlar alone on top of metformin,
or basal insulin compared to metformin and
basal insulin, oral agents, or compared to pla-
cebo alone [5, 7, 9, 10, 12]. A further study—the
LixiLan O trial—tested combined Lixi and iGlar
and iGlar or Lixi alone [8]. In these studies
better glycemic and postprandial control, sig-
nificant lower A1c levels and weight loss were
shown for combined iGlarLixi. Study findings of
the LixiLan or GetGoal trials report comparable
rates of hypoglycemic events (25–40% vs. 33%)
and gastrointestinal adverse events (15–40% vs.
22%) in the combined iGlar and Lixi groups as
found in our study [5, 7–10]. After initiation of
Lixi with basal insulin a significant dose reduc-
tion of nearly 6 units was reported in the Get-
Goal L trial, which is of similar magnitude to
that reported in our study [5].
One of the advantages of combined Lixi and
iGlar treatment was a sufficient decrease of
postprandial glucose levels after breakfast and
lunch, but no suppression of glucose levels after
dinner was noticed. This might be caused by the
half-life of 2–4 h of the short-acting GLP-RA
lixisenatide and displays a potential weakness of
once-daily injected iGlar and Lixi combina-
tions. Conversely, bigger studies including the
LixiLan O trial demonstrated sufficient glucose
level reductions throughout the day and also
around dinner or thereafter after 30 weeks,
albeit increasing glucose levels observed in daily
profiles throughout the day [8].
In our study, the prevalence of responders
with A1c reductions of at least 0.4%
(4 mmol/mol, 5 of 9 patients, 56%) was low. In
44% of patients combined therapy did not
reduce A1c sufficiently. In an RCT a glucose
deterioration was found in 38% of patients with
T2DM switched from insulin to exenatide,
whereas in those who continued insulin gly-
cemic control deteriorated in 19% [13]. Worse
glycemic control was associated with higher





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































and lower C-peptide concentrations, which
proposes a limitation of beta cell secretary
function [13, 14]. However, reports of associa-
tions of duration of T2DM with GLP1-RA
response are heterogeneous, as low and high
diabetes duration as well as no association were
reported [15]. We are not able to show C-pep-
tide levels; however, we observed higher
response defined by A1c reduction of at least
0.4% (19 mmol/mol; i.e., responders) in
patients with higher baseline A1c level (re-
sponders vs non responders: 9.6% vs 8.3%, 81 vs
67 mmol/mol p\0.05, U test), lower but
insignificant baseline BMI (30.2 vs 31.9 kg/m2,
ns), comparable diabetes duration (12.6 vs
11.5 years, ns) and baseline insulin dose (54 vs
58 IU, ns).
However, because of the pilot and proof of
principle character of this study a few limita-
tions are evident. First of all we did not conduct
an RCT. As we intended to prove the feasibility
of the conversion of the glucose-lowering ther-
apy in an outpatient setting we decided to
investigate this in an observational study
design. Thus no direct comparison of effects is
possible as no direct control group is available
and our assumptions are based on these obser-
vations. Moreover, as a result of the study
design we have a low intraindividual variance
using dependent variables with comparison of
pre and post combined therapy. Furthermore
the durations of home glucose profiling receiv-
ing either iPremix (1 week) or combined treat-
ment (12 weeks) were different, making direct
comparisons difficult. Finally, the reliability of
self-monitoring of blood glucose (SMBG) is
limited.
The basal insulin dose was initially set at
60% of the daily iPremix. As shown in Fig. 1 we
constantly had to increase the iGlar dose
throughout the study to decrease high fasting
glucose levels. Because of insufficient iGlar
doses the majority of patients had to correct
with fast acting iGlu at least on an irregular
daily basis. This aspect might also be a reason-
able explanation for the unsatisfactory fasting
glucose levels after 12 weeks on combined Lixi
and iGlar in our study collective, whereas
recently published LixiLan trials could demon-
strated sufficient reduction of fasting glucose
[7, 8]. As a consequence no reduction of insulin
dose seems to be necessary and should be per-
formed in future investigations. Another weak-
ness of the study is the very low number of
patients included, which makes generalization
of results difficult. However, this study was only
designed to prove the principle of safe treat-
ment potential of combined GLP1-RA and
long-acting basal insulin analogue, which was
demonstrated with our results.
CONCLUSION
Our study demonstrates safe application of
combined Lixi and iGlar in patients with poorly
controlled T2DM treated with at least twice-
daily iPremix. Our patients had comparable
glycemic control at the end of the treatment
period, with ameliorated postprandial glucose
profiles throughout the day, which resolves in
the afternoon. Larger and sufficiently powered
RCTs are needed to confirm these findings.
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